Only 47 genes were identified in the previous GWAS of AUD-related phenotypes (Table S2). Twenty-six genes were targets of drugs approved by the FDA or in clinical trials. Among them, four (DRD2, PDE4B, GRM5, and SLC6A9) were drug target genes for AUD treatment (Table S6); for those 22 genes that were targets of drugs to treat diseases other than AUD, 21 were involved in the significant GOBPs identified and five (EIF4E, ESR1, MAPT, METAP1, and TNKS) were reported by previous GWAS of AUD-related phenotypes (Table S2).
